Jw (Cayman) Therapeutics
(OTC) JWCTF
Jw (Cayman) Therapeutics Financials at a Glance
Market Cap
$94.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
CN¥438.93M
Net Income (TTM)
-CN¥1.14B
EPS (TTM)
-$0.19
P/E Ratio
-1.24
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$0.23
Volume
100,000
Open
$0.23
Price
$0.23
Volume
100,000
Open
$0.23
Previous Close
$0.23
Daily Range
$0.23 - $0.23
52-Week Range
$0.23 - $0.66
Estimated Earnings Date
Sep 1, 2026
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$0.23
Volume
100,000
Open
$0.23
Previous Close
$0.23
Daily Range
$0.23 - $0.23
52-Week Range
$0.23 - $0.66
Estimated Earnings Date
Sep 1, 2026
JWCTF News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Jw (Cayman) Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
314
CEO
Feng Tian
Website
www.jwtherapeutics.comHeadquarters
Shanghai, SH, CN
JWCTF Financials
Key Financial Metrics (TTM)
Gross Margin
43.15%
Operating Margin
-105.50%
Net Income Margin
-196.12%
Return on Equity
-75.15%
Return on Capital
-29.51%
Return on Assets
-55.76%
Earnings Yield
-80.65%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$94.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
405.89M
Volume
100.00K
Avg. Volume
8.13K
Financials (TTM)
Gross Profit
CN¥198.44M
Operating Income
-CN¥296.13M
EBITDA
-CN¥609.67M
Operating Cash Flow
-CN¥369.75M
Capital Expenditure
-CN¥6.38M
Free Cash Flow
-CN¥376.13M
Cash & ST Invst.
CN¥503.32M
Total Debt
CN¥262.69M
Jw (Cayman) Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
CN¥174.36M
+102.5%
Gross Profit
CN¥56.00M
+29.0%
Gross Margin
32.12%
N/A
Market Cap
$94.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$336.70K
N/A
Employees
281
N/A
Net Income
-CN¥283.24M
+26.9%
EBITDA
-CN¥138.52M
+38.6%
Quarterly Fundamentals
Total Cash
CN¥503.32M
-50.2%
Total Debt
CN¥262.69M
-17.6%
Accounts Receivable
CN¥2.05M
N/A
Inventory
CN¥62.03M
+78.4%
Long Term Debt
CN¥36.26M
-81.7%
Short Term Debt
CN¥226.32M
+87.0%
Return on Assets
-55.76%
N/A
Return on Invested Capital
-49.96%
N/A
Free Cash Flow
-CN¥29.30M
+82.4%
Operating Cash Flow
-CN¥28.18M
+82.4%